FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s (NYSE:NVS) Pluvicto for prostate cancer patients.

The expanded indication, which approximately triples the number of patients eligible to receive Pluvicto, is based on the Phase 3 PSMAfore trial results.

The patients have prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) and have been treated with an androgen receptor pathway inhibitor (ARPI) therapy.

Also Read: FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease

In ...